ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Research Triangle Park, N.C.-based Nobex is seeking buyers for its intellectual property and assets after declaring bankruptcy in December. On the selling block is its alkylPEGylation technology for conjugating polymers to drug molecules, allowing for oral delivery. Nobex's pipeline includes oral forms of insulin and calcitonin. The bankruptcy comes two years after GlaxoSmithKline pulled out of an alliance with Nobex for oral insulin. India's Biocon subsequently emerged as the new development partner for oral insulin and has submitted an opening bid of $3.5 million for Nobex' assets. Nobex hopes to complete the sale in March.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X